Listen on the go
CORRECT!
Next question
touchINFECTIOUS DISEASES touchINFECTIOUS DISEASES
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • HIV

    An Introduction to HIV

    HIV infection has been a major global problem since its emergence in 1981. Antiretroviral drugs revolutionized the treatment and prevention of HIV, but adherence and the impact on quality of life are ongoing challenges. New longer-acting treatments have recently been introduced to help address these issues, and evolving treatments with a novel mode-of-action are currently under investigation.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

    HIV Content

    Antimicrobial Resistance, COVID-19, HIV, Fungal Infections
    Foreword – touchREVIEWS in Infectious Diseases, Volume 3, Issue 1, 2024

    Welcome to the latest edition of touchREVIEWS in Infectious Diseases, where we continue our mission to deliver insightful, cutting-edge perspectives in infectious disease diagnosis and management. This issue offers an array of topics spanning diagnostics, service delivery innovations and preventive care, reflecting the dynamic challenges and opportunities in our field. In our first editorial, Barbara […]

    HIV
    3d illustration of HIV virus. Medical concept
    World AIDS Day 2024

    The world can eliminate AIDS by empowering communities and prioritizing human rights. We can end AIDS as a global health threat by 2030.   The World Health Organization (WHO) joined forces with partners and communities to commemorate World AIDS Day 2024 (1 December), themed “Take the rights path: My health, my right!”. This year’s campaign […]

    HIV, Sexually Transmitted Infections, Viral Infections
    Greatest Hits of 2024

    As 2024 draws to a close, we’re celebrating a wonderful year of content. From insightful expert Q&As and peer-reviewed articles to conference highlights and a wealth of medical education, it’s been a year filled with content that we hope has been useful to our audience. We’ve had the privilege of connecting with leading experts and working alongside medical societies to support the infectious diseases community with high-quality, easily accessible content.

    HIV, Sexually Transmitted Infections, Viral Infections
    Watch Time: 38 mins
    touchIN CONVERSATION
    Selecting ART: Working with people living with HIV to find the best regimen
    Dr Tristan Barber, Dr Christoph Boesecke Translations available:

    Two experts discuss best practices for antiretroviral therapy (ART) selection for people living with HIV.

    Learning objectives
    Learning Objectives
    • Compare antiretroviral treatment regimens and the implications these differences may have on patients
    • Appraise best practices for shared decision-making when selecting antiretroviral therapies
    • Assess the burden of antiretroviral treatment and the need to change regimen to optimize quality of life
    HIV
    Lenacapavir achieves 100% efficacy in landmark HIV prevention trial

    Topline results from phase III PURPOSE 1 trial (NCT04994509) demonstrate the twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, achieved 100% efficacy in preventing HIV infections in cisgender women.  

    HIV, Sexually Transmitted Infections, Viral Infections
    Watch Time: 38 mins
    touchEXPERT OPINIONS
    Demystifying virology: The link between the HIV life cycle and ART
    Prof. Anne-Mieke Vandamme, Prof. José Arribas, Prof. Antonella Castagna Translations available:

    Watch three experts describe the HIV life cycle, the rationale for ART and how to manage ART resistance.

    Learning objectives
    Learning Objectives
    • Outline the virology of the HIV life cycle and how it is targeted by different antiretroviral therapies
    • Summarize the mechanism of action of current available antiretroviral therapies and the rationale for combining them
    • Discuss the risk of resistance to currently available antiretrovirals and strategies to monitor and manage resistance
    HIV
    Driving Forward After COVID-19: A Call for Continued Investment in Research on Differentiated Models of HIV Service Delivery for Vulnerable Populations Globally
    Danielle Giovenco, Audrey Pettifor, Linda-Gail Bekker

    touchREVIEWS in Infectious Diseases. 2024;3(1):5–6

    The expansion of HIV treatment access during the past two decades, particularly in low- and middle-income countries, stands as a significant accomplishment in the field of public health.1 Currently, there are an estimated 30 million people on antiretroviral treatment for HIV globally, of whom approximately 70% reside in Africa.2 Despite advancements in the provision of antiretroviral therapy […]

    COVID-19, HIV, Vaccines
    Developed by Touch
    HIV vaccine advances: insights from CROI 2024
    Barney Graham Watch Time: 10 mins

    HIV vaccine development harnesses breakthroughs in structure-based antigen design, sequencing, and single-cell analysis to create potent vaccines. Prof. Barney Graham, Professor of Medicine, Microbiology, Chemistry and Immunology, Morehouse School of Medicine in Atlanta, Georgia, USA explores advances reported at CROI 2024, emphasizing advances in targeting antibody lineages and augmenting CD8+ T cell responses, and highlighting sustaining funding models for HIV research and it's imperativeness for addressing broader public health issues.

    COVID-19, HIV, Vaccines
    Developed by Touch
    Pioneering HIV vaccine research through regional advances and vaccine equity
    Barney Graham Watch Time: 9 mins

    HIV vaccine development, emphasizing HIV, RSV, and coronavirus COVID-19 research is discussed by Prof. Barney Graham. This information is crucial for immunologists, virologists, and those in vaccine research. Learn from cross-disciplinary strategies. You, as healthcare professionals in these fields, need to grasp these insights for innovation. HIV, RSV, and coronavirus studies offer valuable lessons. Keep up with the latest in vaccine technology.

    In Partnership with...
    Useful Links:
    About us Society Partners Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchINFECTIOUS DISEASES is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup